NCT03775447 is a clinical trial of Lumbar Puncture in Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.

Who is sponsoring NCT03775447?

NCT03775447 is sponsored by Michael J. Fox Foundation for Parkinson's Research.

What drugs are being tested in NCT03775447?

Interventions in NCT03775447: Lumbar Puncture.

What condition does NCT03775447 study?

NCT03775447 studies Parkinson Disease.

Is NCT03775447 still recruiting?

NCT03775447 is currently completed. Last updated 8 September 2021.

Last reviewed 2021-09-08 · How we verify

NCT03775447

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fox BioNet Project: ECV-003

Completed Last updated 8 September 2021

What this trial tests

trial testing Lumbar Puncture in Parkinson Disease in 38 participants. Completed in 18 December 2019.

Timeline

23 April 2019

Primary endpoint
18 December 2019

18 December 2019

Quick facts

Lead sponsor	Michael J. Fox Foundation for Parkinson's Research
Status	Completed
Study type	OBSERVATIONAL
Enrollment	38
Start date	23 April 2019
Primary completion	18 December 2019
Estimated completion	18 December 2019
Sites	3 locations across United States

Drugs / interventions tested

Lumbar Puncture — full drug profile →

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Michael J. Fox Foundation for Parkinson's Research

Who can join

18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to optimize pre-analytical cerebrospinal fluid (CSF) extracellular vesicle isolation protocols for increasing the detection of LRRK2 activity in human CSF

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The role of extracellular vesicles in the physiological and pathological regulation of the blood-brain barrier.
Busatto S, Morad G, Guo P, Moses MA. · · 2021 · cited 66× · PMID 34485835 · DOI 10.1096/fba.2021-00045
Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson's Disease.
Leggio L, Paternò G, Vivarelli S, Falzone GG, et al · · 2021 · cited 38× · PMID 34527424 · DOI 10.14336/ad.2021.0527
Emerging Role of Extracellular Vesicles as Biomarkers in Neurodegenerative Diseases and Their Clinical and Therapeutic Potential in Central Nervous System Pathologies.
Malaguarnera M, Cabrera-Pastor A. · · 2024 · cited 30× · PMID 39337560 · DOI 10.3390/ijms251810068
Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules.
Natale F, Fusco S, Grassi C. · · 2022 · cited 29× · PMID 36437458 · DOI 10.1186/s40035-022-00326-w
Extracellular vesicles: biological mechanisms and emerging therapeutic opportunities in neurodegenerative diseases.
Wang L, Zhang X, Yang Z, Wang B, et al · · 2024 · cited 26× · PMID 39643909 · DOI 10.1186/s40035-024-00453-6
Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis.
Tran HL, Zheng W, Issadore DA, Im H, et al · · 2025 · cited 25× · PMID 40720603 · DOI 10.1021/acsnano.5c00706
Extracellular Vesicles as Biomarkers for Parkinson's Disease: How Far from Clinical Translation?
Gualerzi A, Picciolini S, Bedoni M, Guerini FR, et al · · 2024 · cited 17× · PMID 38256215 · DOI 10.3390/ijms25021136
Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions.
Choi HK, Chen M, Goldston LL, Lee KB. · · 2024 · cited 11× · PMID 38739358 · DOI 10.1186/s40580-024-00426-5

Verify or expand the search:

Other trials of Lumbar Puncture

Trials testing the same drug.

NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07069699 — Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene · Phase 1, PHASE2 · recruiting
NCT06816979 — Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell · NA · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07466316 — A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Ove · Phase 3 · not yet recruiting

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Michael J. Fox Foundation for Parkinson's Research trials

Trials by the same sponsor.

NCT04906590 — PPMI Tau PET Imaging · Phase 2 · completed
NCT04603326 — FoxBioNet: ECV (Extracellular Vesicle) 004 · completed
NCT06719583 — Black and African Americans Connections to Parkinson's Disease (BLAAC PD) · recruiting
NCT03545425 — Fox BioNet Project: LRRK2-002 · completed
NCT03170063 — FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03775447 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michael J. Fox Foundation for Parkinson's Research
Last refreshed: 8 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03775447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing